Some institutional investors have already research
Post# of 148179
An EUA and/or uplisting will get the attention of these bigger investors, and when their reseach takes them to leronlimab's history against covid-19 and then to all the other diseases and trials, it will get exciting.
Can't imagine buying say 50,000 shares at under a dollar, that wasn't me.
I am diversified as I've said before, I bought CYDY at 8 different share prices, all above $3.00